StocksFundsScreenerSectorsWatchlists
AMED

AMED - Amedisys Inc Stock Price, Fair Value and News

91.36USD+0.01 (+0.01%)Market Closed

Market Summary

AMED
USD91.36+0.01
Market Closed
0.01%

AMED Stock Price

View Fullscreen

AMED RSI Chart

AMED Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

-306.06

Price/Sales (Trailing)

1.33

EV/EBITDA

33.98

Price/Free Cashflow

22.67

AMED Price/Sales (Trailing)

AMED Profitability

EBT Margin

1.77%

Return on Equity

-0.91%

Return on Assets

-0.47%

Free Cashflow Yield

4.41%

AMED Fundamentals

AMED Revenue

Revenue (TTM)

2.2B

Rev. Growth (Yr)

1.55%

Rev. Growth (Qtr)

2.62%

AMED Earnings

Earnings (TTM)

-9.7M

Earnings Growth (Yr)

-39.08%

Earnings Growth (Qtr)

-25.57%

Breaking Down AMED Revenue

Last 7 days

-1.1%

Last 30 days

-2.0%

Last 90 days

-4.0%

Trailing 12 Months

12.7%

How does AMED drawdown profile look like?

AMED Financial Health

Current Ratio

1.05

Debt/Equity

0.34

Debt/Cashflow

0.38

AMED Investor Care

Shares Dilution (1Y)

0.36%

Diluted EPS (TTM)

-0.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20232.2B2.2B2.2B2.2B
20222.2B2.2B2.2B2.2B
20212.1B2.2B2.2B2.2B
20202.0B2.0B2.0B2.1B
20191.7B1.8B1.9B2.0B
20181.5B1.6B1.6B1.7B
20171.5B1.5B1.5B1.5B
20161.3B1.4B1.4B1.4B
20151.2B1.2B1.2B1.3B
20141.2B1.2B1.2B1.2B
20131.4B1.4B1.3B1.2B
20121.5B1.5B1.5B1.4B
20111.6B1.5B1.5B1.5B
20101.5B1.6B1.6B1.6B
20091.3B1.4B1.4B1.5B
20080861.1M1.0B1.2B
2007000697.9M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Amedisys Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 20, 2024
bohnert denise m.
sold (taxes)
-132,571
93.69
-1,415
chief compliance officer
Feb 20, 2024
ginn scott g
sold (taxes)
-301,494
93.69
-3,218
evp, cfo & coo
Feb 20, 2024
north michael paul
sold (taxes)
-149,061
93.69
-1,591
chief information officer
Feb 20, 2024
muscato nick
sold (taxes)
-30,636
93.69
-327
chief strategy officer
Feb 16, 2024
ginn scott g
acquired
-
-
16,553
evp, cfo & coo
Feb 16, 2024
muscato nick
acquired
-
-
5,518
chief strategy officer
Feb 16, 2024
north michael paul
acquired
-
-
8,277
chief information officer
Feb 16, 2024
bohnert denise m.
acquired
-
-
5,518
chief compliance officer
Feb 16, 2024
ashworth richard m
acquired
-
-
55,175
president and ceo
Feb 16, 2024
holton adam y
acquired
-
-
5,518
chief people officer

1–10 of 50

Which funds bought or sold AMED recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 15, 2024
Legato Capital Management LLC
unchanged
-
-26,065
828,334
0.10%
Apr 15, 2024
St. Johns Investment Management Company, LLC
unchanged
-
-41.00
1,290
-%
Apr 15, 2024
JANICZEK WEALTH MANAGEMENT, LLC
unchanged
-
-409
12,995
-%
Apr 15, 2024
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC
reduced
-11.36
-39,542
241,644
-%
Apr 15, 2024
EXCHANGE TRADED CONCEPTS, LLC
added
3.11
-205
619,776
0.02%
Apr 12, 2024
AdvisorNet Financial, Inc
sold off
-100
-665
-
-%
Apr 12, 2024
Bridge City Capital, LLC
added
0.78
-64,638
2,751,990
1.00%
Apr 11, 2024
CONTRAVISORY INVESTMENT MANAGEMENT, INC.
reduced
-0.11
-8,133
249,385
0.06%
Apr 10, 2024
Banque Cantonale Vaudoise
new
-
60,000
60,000
-%
Apr 10, 2024
Bruce G. Allen Investments, LLC
added
350
639
829
-%

1–10 of 45

Are Funds Buying or Selling AMED?

Are funds buying AMED calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AMED
No. of Funds

Unveiling Amedisys Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.86%
3,218,592
SC 13G/A
Feb 12, 2024
flynn james e
0%
0
SC 13G/A
Feb 08, 2024
wellington management group llp
0.00%
24
SC 13G/A
Jan 24, 2024
blackrock inc.
9.1%
2,964,393
SC 13G/A
Jul 06, 2023
jpmorgan chase & co
2.3%
774,361
SC 13G/A
May 18, 2023
flynn james e
5.51%
1,794,000
SC 13G
Feb 14, 2023
ameriprise financial inc
3.39%
1,100,719
SC 13G/A
Feb 09, 2023
vanguard group inc
9.63%
3,128,416
SC 13G/A
Feb 06, 2023
wellington management group llp
8.63%
2,802,831
SC 13G/A
Jan 26, 2023
blackrock inc.
12.6%
4,106,566
SC 13G/A

Recent SEC filings of Amedisys Inc

View All Filings
Date Filed Form Type Document
Mar 19, 2024
8-K
Current Report
Feb 22, 2024
10-K
Annual Report
Feb 21, 2024
8-K
Current Report
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 13, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Amedisys Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
432.4B
371.6B
-9.23% -12.95%
19.32
1.16
14.64% 11.24%
101.4B
195.3B
-0.90% 34.65%
18.87
0.52
8.17% -20.79%
86.8B
357.8B
-10.90% -7.68%
10.4
0.24
10.95% 93.52%
83.0B
65.0B
0.18% 18.00%
15.84
1.28
7.86% -7.11%
38.7B
154.0B
-3.67% 6.80%
14.31
0.25
6.54% 124.79%
11.4B
12.1B
-4.93% 54.73%
16.46
0.94
4.57% 23.40%
11.2B
14.3B
-4.30% 22.39%
15.59
0.78
6.59% 6.24%
MID-CAP
9.2B
2.3B
-4.81% 9.59%
33.75
4.06
6.06% 9.17%
6.7B
2.9B
-6.00% -3.46%
-311.45
2.3
12.20% -107.93%
2.2B
3.8B
-2.74% -34.13%
10.21
0.57
-27.73% -52.50%
2.1B
1.4B
-1.50% 0.56%
34.59
1.51
21.19% 34.42%
SMALL-CAP
1.6B
1.1B
0.06% -12.91%
25.15
1.48
11.31% 35.83%
1.2B
3.0B
5.33% 55.67%
-6.31
0.4
6.74% 20.73%
48.4M
-
-23.65% -14.81%
-3.31
-
- -12.94%
18.7M
21.3M
11.67% 2.14%
35.03
0.88
8.00% -62.25%

Amedisys Inc News

Latest updates
MarketBeat11 hours ago
Yahoo Finance25 Mar 202407:00 am
Yahoo Finance20 Mar 202407:00 am

Amedisys Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue2.6%571556553556562558558545559553564537551544485492501495493467434
Costs and Expenses4.4%537514515514516519510497511497491477495486458448459448448423398
EBITDA Margin-5.1%0.04*0.04*0.04*0.09*0.09*0.10*0.11*0.13*0.14*0.15*0.16*0.13*---------
Interest Expenses2.7%8.008.008.008.006.005.008.003.003.003.002.002.002.003.003.003.003.004.004.003.002.00
Income Taxes-17.5%10.0012.0018.0010.0010.009.0011.0012.0013.0011.0029.0018.0016.00-10.2010.009.0011.0010.0010.0011.009.00
Earnings Before Taxes-23.1%29.0038.00-62.2335.0041.0035.0040.0044.0047.0056.0010968.0062.0062.0045.0041.0039.0044.0044.0042.0037.00
EBT Margin-23.8%0.02*0.02*0.02*0.07*0.07*0.07*0.08*0.12*0.13*0.13*0.14*0.11*---------
Net Income-25.6%19.0026.00-80.2825.0032.0026.0030.0032.0034.0045.0080.0050.0045.0072.0035.0032.0028.0034.0034.0031.0028.00
Net Income Margin-466.5%0.00*0.00*0.00*0.05*0.05*0.05*0.06*0.09*0.09*0.10*0.11*0.10*---------
Free Cashflow639.6%58.00-10.8359.0025.0039.00-15.1956.0048.004.0060.0067.0052.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets1.6%2,0602,0271,9821,9471,9761,9822,0011,9081,8571,9381,6001,5731,5671,6031,6451,4401,2631,2121,2061,184717
  Current Assets6.4%497467427406389389395392357433391380362411450468351300276272224
    Cash Equivalents61.9%12678.0095.0049.0041.0031.0049.0071.0046.0012893.0078.0083.0011518017896.0021.0014.0011.0020.00
  Net PPE5.5%42.0040.0036.0033.0016.0017.0018.0017.0018.0020.0021.0022.0024.0024.0025.0026.0028.0030.0030.0030.0029.00
  Goodwill0.0%1,2451,2451,2451,2451,2871,2851,2909.001,1961,188937933933931937721659660665650330
Liabilities0.7%940934922814870913962888881989724784756845923760621609643663234
  Current Liabilities1.2%474468462353356367427380374454449456456437442316327315313297222
  Long Term Debt-1.4%3623673703734194434424294324351792312053013933802322322663046.00
    LT Debt, Current-------------10.00---10.00---2.00
    LT Debt, Non Current-------------205---232---6.00
Shareholder's Equity2.6%1,0671,0401,0611,1331,0521,0701,0391,021976949876790811758722680642603563521483
  Retained Earnings2.7%748729703783758726700671639605560480430385313278246219185151120
  Additional Paid-In Capital1.3%787777769759755751743737728721714707698690666656645635623614604
Accumulated Depreciation-1.6%92.0094.0091.0010510110210099.0097.0010099.0098.0095.0010210198.0096.0010199.0097.0095.00
Shares Outstanding0.1%33.0033.0033.0033.0033.0032.0033.0033.0033.0033.0033.0033.00---------
Minority Interest-0.6%53.0054.0054.0054.0055.0054.0053.0054.0045.0044.002.001.002.002.001.001.001.001.001.001.001.00
Float---2,600---3,000---6,900---5,500---2,800--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations712.7%60,311-9,84360,75925,96140,883-13,63057,40948,6215,16661,76767,95854,00265,91283,083133,9226,03575,22047,45559,26620,05964,033
  Share Based Compensation29.8%9,4007,2439,1083,2735703,4955,1487,3475,9404,3976,1567,3076,9727,1246,7255,9096,5896,2985,5386,6155,234
Cashflow From Investing-94.6%-2,039-1,048-7,74545,896-1,866-1,033-75,508-16,079-11,667-264,561-3,822-1,557-1,565-1,221-213,567-70,755-1,386-3,604-19,046-328,912-9,572
Cashflow From Financing-114.7%-13,425-6,254-10,953-56,890-16,344-2,641-4,046-7,402-75,938238,356-49,834-57,458-96,443-146,73682,160146,0421,899-36,996-36,872299,178-48,242
  Buy Backs-------17,351-14,99910,8051,18872,886---------

AMED Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Net service revenue$ 2,236,382$ 2,223,199$ 2,214,112
Other operating income0013,300
Cost of service, inclusive of depreciation1,245,5091,260,4251,233,356
General and administrative expenses:   
Salaries and benefits516,049508,791474,718
Non-cash compensation26,08216,56023,809
Merger-related expenses36,67200
Depreciation and amortization17,74724,93530,901
Investment impairment03,0090
Other237,929228,707212,713
Total operating expenses2,079,9882,042,4271,975,497
Operating income156,394180,772251,915
Other income (expense):   
Interest income3,27017849
Interest expense(31,274)(22,228)(9,525)
Equity in earnings (loss) from equity method investments10,760(45)4,949
Merger termination fee(106,000)00
Gain on equity method investments0031,098
Miscellaneous, net6,4731,5671,745
Total other (expense) income, net(116,771)(20,528)28,316
Income before income taxes39,623160,244280,231
Income tax expense(50,559)(42,545)(70,065)
Net (loss) income(10,936)117,699210,166
Net loss (income) attributable to noncontrolling interests1,189910(1,094)
Net (loss) income attributable to Amedisys, Inc.$ (9,747)$ 118,609$ 209,072
Basic earnings per common share:   
Net (loss) income attributable to Amedisys, Inc. common stockholders (usd per share)$ (0.30)$ 3.65$ 6.41
Weighted average shares outstanding (shares)32,59932,51732,642
Diluted earnings per common share:   
Net (loss) income attributable to Amedisys, Inc. common stockholders$ (0.30)$ 3.63$ 6.34
Weighted average shares outstanding (shares)32,59932,65332,972

AMED Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 126,450$ 40,540
Restricted cash12,41313,593
Patient accounts receivable313,373296,785
Prepaid expenses14,63911,628
Other current assets30,06026,415
Total current assets496,935388,961
Property and equipment, net of accumulated depreciation of $92,422 and $101,36441,84516,026
Operating lease right of use assets88,939102,856
Goodwill1,244,6791,287,399
Intangible assets, net of accumulated amortization of $14,008 and $14,604102,675101,167
Other assets85,09779,836
Total assets2,060,1701,976,245
Current liabilities:  
Accounts payable28,23743,735
Payroll and employee benefits136,835125,387
Accrued expenses140,049137,390
Termination fee paid by UnitedHealth Group106,0000
Current portion of long-term obligations36,31415,496
Current portion of operating lease liabilities26,28633,521
Total current liabilities473,721355,529
Long-term obligations, less current portion361,862419,420
Operating lease liabilities, less current portion62,75169,504
Deferred income tax liabilities40,63520,411
Other long-term obligations1,4184,808
Total liabilities940,387869,672
Commitments and Contingencies
Equity:  
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding00
Common stock, $0.001 par value, 60,000,000 shares authorized; 38,131,478 and 37,891,186 shares issued; and 32,667,631 and 32,511,465 shares outstanding3838
Additional paid-in capital787,177755,063
Treasury stock at cost, 5,463,847 and 5,379,721 shares of common stock(468,626)(461,200)
Retained earnings747,925757,672
Total Amedisys, Inc. stockholders’ equity1,066,5141,051,573
Noncontrolling interests53,26955,000
Total equity1,119,7831,106,573
Total liabilities and equity$ 2,060,170$ 1,976,245
AMED
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
 CEO
 WEBSITEamedisys.com
 INDUSTRYHealthcare Plans
 EMPLOYEES20000

Amedisys Inc Frequently Asked Questions


What is the ticker symbol for Amedisys Inc? What does AMED stand for in stocks?

AMED is the stock ticker symbol of Amedisys Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amedisys Inc (AMED)?

As of Mon Apr 15 2024, market cap of Amedisys Inc is 2.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMED stock?

You can check AMED's fair value in chart for subscribers.

What is the fair value of AMED stock?

You can check AMED's fair value in chart for subscribers. The fair value of Amedisys Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amedisys Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMED so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amedisys Inc a good stock to buy?

The fair value guage provides a quick view whether AMED is over valued or under valued. Whether Amedisys Inc is cheap or expensive depends on the assumptions which impact Amedisys Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMED.

What is Amedisys Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, AMED's PE ratio (Price to Earnings) is -306.06 and Price to Sales (PS) ratio is 1.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMED PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Amedisys Inc's stock?

In the past 10 years, Amedisys Inc has provided 0.208 (multiply by 100 for percentage) rate of return.